Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma

J Invest Dermatol. 2015 Nov;135(11):2873-2876. doi: 10.1038/jid.2015.252. Epub 2015 Jul 2.

Authors

Anupam Mitra¹, Jesus I Luna¹, Alina I Marusina¹, Alexander Merleev¹, Smriti Kundu-Raychaudhuri², David Fiorentino³, Siba P Raychaudhuri², Emanual Maverakis⁴

Affiliations

¹ Department of Dermatology, School of Medicine, University of California Davis, Sacramento, California, USA.
² School of Medicine, University of California Davis, VA Medical Center Sacramento, Mather, California, USA.
³ Department of Dermatology, Stanford University, Redwood City, California, USA.
⁴ Department of Dermatology, School of Medicine, University of California Davis, Sacramento, California, USA. Electronic address: emaverakis@yahoo.com.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers / metabolism
Biopsy, Needle
Cells, Cultured
Fibroblasts
Fibrosis / drug therapy
Fibrosis / prevention & control
Humans
Imidazoles / pharmacology
Immunohistochemistry
Molecular Targeted Therapy
Phosphorylation / drug effects
Polymerase Chain Reaction / methods
Scleroderma, Diffuse / drug therapy*
Scleroderma, Diffuse / metabolism
Scleroderma, Diffuse / pathology*
Sensitivity and Specificity
Sirolimus / pharmacology*
Smad2 Protein / drug effects
Smad2 Protein / metabolism
TOR Serine-Threonine Kinases / drug effects
TOR Serine-Threonine Kinases / metabolism*
Transforming Growth Factor beta / drug effects
Transforming Growth Factor beta / metabolism*
Triazines / pharmacology

Substances

Biomarkers
Imidazoles
OSI 027
Smad2 Protein
Transforming Growth Factor beta
Triazines
MTOR protein, human
TOR Serine-Threonine Kinases
Sirolimus

Grants and funding